ETFs Investing in Beta Bionics, Inc. Stocks
This article lists several ETFs that invest in Beta Bionics, Inc. (BBNX) stocks, providing details such as market value, weight, issuer, expense ratio, and performance. The ETFs offer investors diversified exposure to the medical technology sector and small-cap companies, among others. The information aims to help investors identify funds that include BBNX, making stock investing more accessible with lower risk.
Price to earnings forward of Beta Bionics, Inc. – NASDAQ:BBNX
This article focuses on the "Price to earnings forward" financial metric for Beta Bionics, Inc. (NASDAQ: BBNX) as reported by TradingView. The page displays the company's stock information, along with navigation to various financial and community features on the TradingView platform.
Enterprise value to EBITDA forward of Beta Bionics, Inc. – NASDAQ:BBNX
This article provides financial data for Beta Bionics, Inc. (NASDAQ: BBNX), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial data snippet from TradingView, indicating the period, value, and change for this specific financial ratio for the company.
CFO trades 10,000 Beta Bionics (BBNX) shares under Rule 10b5-1 plan
Beta Bionics' Chief Financial Officer, Stephen Feider, executed an amended insider transaction, exercising options for 10,000 shares and subsequently selling them on the open market. The sales, conducted on June 26 and June 29, 2026, were made under a pre-arranged Rule 10b5-1 trading plan. This amendment clarifies the number of shares from a previous option exercise and updates his beneficial ownership, which now stands at 166,053 shares directly held.
Beta Bionics CFO Stephen Feider sells $170k of BBNX stock
Stephen Feider, CFO of Beta Bionics (NASDAQ:BBNX), sold 10,000 shares of company stock for a total of approximately $170,387 across two transactions in late June. These sales were made under a Rule 10b5-1 trading plan and occurred concurrently with the exercise of employee stock options for the same number of shares. The company's stock is currently trading at $16.77, and recent reports indicate Beta Bionics surpassed Q1 revenue estimates and raised its guidance.
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics, Inc. announced its plan to release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss its performance. The webcast link and dial-in details will be available on the company's investor relations website.
Beta Bionics sets July 29 call for Q2 2026 results
Beta Bionics (Nasdaq: BBNX) announced it will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Management will host a conference call and webcast on the same day at 4:30 pm ET to discuss the quarterly performance. The announcement caused a positive market reaction, with BBNX shares gaining 6.57%.
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics, Inc. (Nasdaq: BBNX) announced it will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss its performance. The webcast link will be available on the company's investor relations website.
Beta Bionics to announce Q2 2026 financial results on July 29
Beta Bionics will release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The medical device company, known for its iLet Bionic Pancreas, will host a conference call and webcast at 4:30 pm ET on the same day to discuss its performance. The webcast will be available on the "Investors—Events & Presentations" section of their website for replay.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations, focusing on whether the company made misleading statements regarding its growth and operating metrics. This investigation comes after Beta Bionics reported Q4 2025 new patient starts that fell below analyst expectations and showed a significant deceleration in growth. Investors who suffered losses in Beta Bionics securities are encouraged to contact Johnson Fistel to explore their legal rights.
Beta Bionics (BBNX) CFO sells 10,000 shares under 10b5-1 trading plan
Beta Bionics, Inc. (BBNX) Chief Financial Officer Stephen Feider sold 10,000 shares of common stock in open-market transactions between June 26 and June 29, 2026, at weighted average prices around $17.04. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in May 2025, following the exercise of stock options for 9,878 shares at $5.10 each. Feider retained a significant equity position, directly holding 165,931 shares after these transactions.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLP is investigating potential securities law violations on behalf of Beta Bionics, Inc. investors due to concerns about false or misleading statements regarding the Company’s growth trends and business outlook. The investigation focuses on slower new patient start growth reported for Q4 2025, which fell below analyst expectations despite year-over-year growth. Johnson Fistel encourages investors who suffered losses to join the investigation.
Form 144 Beta Bionics For: 29 June By Investing.com
This article announces the filing of Form 144 for Beta Bionics on June 29. It provides stock market data, including various indices, commodities, and individual stock performances, alongside a list of popular news articles from Investing.com. The information is presented as a snapshot of market activity.
BBNX (NASDAQ: BBNX) notice: proposed sale of 4,896 shares on 06/29/2026
BBNX (NASDAQ: BBNX) has filed a Form 144 notice for the proposed sale of 4,896 shares of Common Stock, identified as stock options, to be sold for cash on June 29, 2026. The filing indicates 44,561,695 shares outstanding as of the same date. Additionally, it records prior sales by Stephen Feider totaling 11,780 shares in June 2026.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations after the company disclosed slower new patient start growth for Q4 2025, which fell below analyst expectations despite overall year-over-year growth. The investigation focuses on whether Beta Bionics made false or misleading statements regarding its growth trends, new patient starts, and business outlook. Investors who suffered losses after purchasing Beta Bionics securities are encouraged to join the investigation.
Beta Bionics, Inc.(NasdaqGM: BBNX) dropped from Russell 2000 Growth Benchmark
Beta Bionics, Inc. (BBNX) has been removed from the Russell 2000 Growth Benchmark. The medical device company, known for its iLet Bionic Pancreas for diabetes management, also saw its shares drop +1.07% on the day this news was published. This change in index inclusion follows several recent updates from the company, including news on its product development and financial performance.
Beta Bionics, Inc.(NasdaqGM: BBNX) dropped from Russell 2500 Growth Benchmark
Beta Bionics, Inc. (BBNX) has been removed from the Russell 2500 Growth Benchmark, as announced on June 28, 2026. This follows other recent removals from the Russell 2000 Growth, Russell 3000E Growth, and Russell 3000 Growth benchmarks. The company is a medical device firm focused on solutions for insulin-requiring people with diabetes, notably its iLet Bionic Pancreas.
Beta Bionics (BBNX) CCO logs 1,258-share Rule 10b5-1 stock sale
Beta Bionics' Chief Commercial Officer, Mark Hopman, reported an open-market sale of 1,258 shares of common stock on June 24, 2026. The sale, conducted under a pre-arranged Rule 10b5-1 Plan adopted in May 2025, occurred at a weighted average price of $15.0083 per share. Following this transaction, Hopman directly holds 129,354 shares of BBNX.
Director Christy Jones sells BBNX shares under Rule 10b5-1 plan
Beta Bionics director Christy Jones sold 1,406 shares of BBNX Common Stock at $15.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026. Following this transaction, she now directly holds 25,994 shares. The sale, valued at $21,090, was disclosed in a Form 4 filing with the SEC, indicating a planned, rather than discretionary, reduction in her holdings.
BBNX Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Beta Bionics, Inc. (BBNX) for 2027, based on analyst opinions. It details the company's financial performance, including past earnings and revenue, future earnings report dates, and key financial metrics like EBITDA. The article also addresses frequently asked questions about BBNX stock, such as its ticker, all-time high and low prices, and information on dividends and employee count.
Beta Bionics, Inc. Actuals & Estimates (BOATS:BBNX)
This article provides an overview of Beta Bionics, Inc.'s (BBNX) financial actuals, estimates, and analyst forecasts. It covers details like stock tickers, price targets, historical highs and lows, upcoming earnings dates, recent earnings per share and revenue figures, net income, EBITDA, and employee count. The piece also addresses frequently asked questions about the company's financial performance and stock trading.
Beta Bionics director Christy Jones sells $21,090 in stock
Beta Bionics director Christy Jones sold 1,406 shares of the company’s common stock for $21,090 on June 24, 2026, as part of a pre-planned trading arrangement. This transaction occurred amidst a 52.6% decline in Beta Bionics stock over the past six months, even though the company recently reported strong first-quarter revenue and raised its guidance, with several analysts maintaining positive ratings despite adjusted price targets.
10b5-1 sales reported for BBNX insider Christina Jones (NASDAQ: BBNX)
BBNX insider Christina Jones filed a Form 144 reporting planned and recent Rule 10b5-1 sales of restricted stock units. The filing details sales on May 21, 2026, and June 4, 2026, with specific amounts, and relates to Restricted Stock Units dated September 1, 2025. This document serves as a routine notice of affiliate sales under a pre-arranged trading plan.
Lake Street Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $20
Lake Street has reiterated its Buy rating for Beta Bionics (BBNX.US), maintaining a target price of $20. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Form 144 Beta Bionics For: 24 June By Investing.com
This article from Investing.com reports on Form 144 for Beta Bionics for June 24. It is a brief financial news update indicating a filing related to the company. The content also features various market data including indices, commodities, and bond performances.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (BBNX) for potential securities law violations after the company's disclosure of slower new patient start growth for Q4 2025. Investors who suffered losses after purchasing Beta Bionics securities are encouraged to contact Johnson Fistel to discuss their legal rights, as the growth figures were below analyst expectations and showed a significant deceleration.
Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Regeneron (REGN) and Alkermes (ALKS)
Analysts have provided insights into several healthcare companies: Beta Bionics, Inc. (BBNX) received a reiterated Buy rating from Piper Sandler with a $20.00 price target. Regeneron (REGN) was maintained as a Hold by Citi with a $700.00 price target. Alkermes (ALKS) received a reiterated Buy rating from Piper Sandler with a price target of $43.00, reflecting a Strong Buy consensus among analysts.
Beta Bionics Inc (BBNX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Beta Bionics Inc (BBNX) currently holds an earnings forecast score of 8.17, ranking 61st in its industry, with an average analyst price target of $32.00. Analysts largely recommend a "Buy" for BBNX stock, forecasting an expected revenue of $31.55 million for the next quarter. The company's previous quarter's EPS of -$0.30 surpassed the market expectation of -$0.49, and the EPS for the upcoming quarter is projected at -$0.59.
Beta Bionics (Nasdaq:BBNX) - Stock Analysis
Beta Bionics (Nasdaq:BBNX) is a commercial-stage medical device company focused on diabetes solutions, with a current market cap of US$618.5m and a share price of US$13.88, deemed 44.5% undervalued by analysts. The company announced an updated commercialization timeline for its Mint Patch Pump, expecting full commercialization by Q2 2027, and recently raised its earning guidance for the full year 2026. Despite revenue growth forecasts and positive product developments, risks include current unprofitability, significant insider selling, and high share price volatility.
Beta Bionics Inc (BBNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Beta Bionics Inc (BBNX), detailing its business segments for FY2025. The company's revenue is primarily generated through two channels: DME (Durable Medical Equipment) and PBP (Pharmacy Benefit Manager), with iLet and single-use products contributing to these figures. The data current as of April 6, 2025, shows that the DME channel for iLet products represents the largest portion of the revenue.
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Johnson Fistel, PLLP is investigating Beta Bionics (BBNX) for potential securities law violations after the company disclosed slower new patient start growth for Q4 2025. This deceleration, from 68% to 36% year-over-year growth, fell short of analyst expectations and may have impacted investors who relied on the company's previous growth trends. Investors who suffered losses are encouraged to contact Johnson Fistel for more information on their legal rights.
Beta Bionics (BBNX) Securities Investigation: Johnson
Johnson Fistel, PLLP is investigating potential securities law violations concerning Beta Bionics, Inc. (NASDAQ: BBNX) following the company's disclosure of slower-than-expected new patient start growth for Q4 2025. The investigation focuses on whether Beta Bionics or its officers made misleading statements regarding growth trends and business outlook, which may have impacted investors who relied on these metrics. Investors who suffered losses after purchasing Beta Bionics securities are encouraged to join the investigation.
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Johnson Fistel, PLLP is investigating potential securities law violations concerning Beta Bionics (BBNX) after the company reported slower new patient start growth for Q4 2025. The investigation focuses on whether Beta Bionics made misleading statements or failed to disclose material information regarding its growth trends and business outlook. Investors who suffered losses after purchasing Beta Bionics securities are encouraged to contact Johnson Fistel to discuss their legal rights.
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Johnson Fistel, PLLP has initiated a securities investigation into Beta Bionics, Inc. (NASDAQ: BBNX) following the company's disclosure of slower new patient start growth for Q4 2025. The investigation will determine if Beta Bionics or its executives made misleading statements regarding growth trends, new patient starts, and business outlook. Investors who suffered losses are encouraged to join the investigation.
Beta Bionics | 4: Statement of changes in beneficial ownership of securities-Director Jones Christy
This article from moomoo Investments reports on a Statement of changes in beneficial ownership of securities for Director Jones Christy of Beta Bionics. The announcement refers to a separate document, Doc 1. The content also includes extensive risk disclaimers regarding investment information.
Have Beta Bionics Insiders Been Selling Stock?
Beta Bionics' President, Sean Saint, recently sold US$213k worth of shares, though this only represents 3.9% of his total holding. Over the last year, there have been no insider purchases, only sales, leading to caution regarding the stock despite insiders still owning 5.6% of the company. These insider transactions suggest a cautious outlook for the company's stock.
Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information
Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) after the company's stock price declined over 35% on January 9, 2026. This drop followed Beta Bionics' preliminary Q4 2025 financial results, which showed new patient starts below analyst expectations and a slowdown in year-over-year growth. The law firm is looking into whether certain officers and directors violated securities laws and breached their fiduciary duties to shareholders.
Beta bionics CCO Mark Hopman sells $3,385 in shares
Mark Hopman, CCO of Beta Bionics (NASDAQ:BBNX), sold 275 shares worth $3,385 on June 4, 2026, pursuant to a pre-arranged trading plan. This transaction leaves him with 130,612 directly owned shares. The company's stock has since gained 14.6%, and Beta Bionics recently exceeded Q1 revenue estimates and raised its guidance, leading to mixed analyst responses.
Beta bionics director Jones Christy sells $39,354 in stock
Jones Christy, a director at Beta Bionics Inc. (NASDAQ:BBNX), sold 2,811 shares of company stock for $39,354 on June 4, 2026, pursuant to a Rule 10b5-1 Plan. Following the sale, Christy still holds 27,400 shares. This transaction comes amidst recent company news, including exceeding first-quarter revenue estimates and adjusting analyst price targets, while Beta Bionics also launched a public dashboard for its iLet Bionic Pancreas data.
Beta bionics CCO Mark Hopman sells $3,385 in shares
Mark Hopman, CCO of Beta Bionics (NASDAQ:BBNX), sold 275 shares for $3,385 on June 4, 2026, as part of a Rule 10b5-1 trading plan. The company's stock has seen a 14.6% gain recently, although InvestingPro analysis suggests it may be overvalued. Beta Bionics also reported strong Q1 revenue, raised its guidance, and launched a public dashboard for its iLet Bionic Pancreas.
Beta Bionics (BBNX) CCO logs small 275-share sale under Rule 10b5-1 plan
Beta Bionics CCO Mark Hopman sold 275 shares of common stock at $12.31 per share under a pre-arranged Rule 10b5-1 Plan. After this transaction, he directly holds 130,612 shares. The sale is considered routine as per the plan adopted in May 2025 and is identified as neutral in impact and sentiment.
Beta Bionics (NASDAQ: BBNX) director sells 2,811 shares in planned trade
Beta Bionics (NASDAQ: BBNX) director Christy Jones sold 2,811 shares of common stock at $14.00 per share on June 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 Plan adopted in February 2026. Following the sale, Jones retains 27,400 shares, indicating a significant ongoing equity position in the company.
Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information
Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) after its stock price declined over 35% following preliminary Q4 2025 financial results. The company's new patient starts were below analyst expectations, indicating a slowdown. The law firm is examining whether Beta Bionics officers and directors violated securities laws and breached fiduciary duties.
Beta Bionics (BBNX) Securities Investigation: Johnson
Johnson Fistel, PLLP is investigating Beta Bionics (NASDAQ: BBNX) for potential securities law violations after the company disclosed slower new patient start growth for Q4 2025. This deceleration, which fell below analyst expectations despite overall growth, has raised concerns for investors. The law firm is encouraging affected Beta Bionics shareholders to join its investigation to explore their legal rights.
Have Beta Bionics Insiders Been Selling Stock?
Beta Bionics, Inc. recently saw its President, Sean Saint, sell US$213k worth of shares, representing 3.9% of his total holding. While this was the largest insider sale in the past year, no insiders have purchased shares during the same period. Despite a strong insider ownership of 5.6%, the history of sales leads to a cautious outlook on the stock.
Beta Bionics | 144: Notice of proposed sale of securities pursuant to Rule 144
This document is a formal Notice of Proposed Sale of Securities pursuant to Rule 144 for Beta Bionics. This indicates an intention to sell restricted or controlled securities of the company.
Beta Bionics | 144: Notice of proposed sale of securities pursuant to Rule 144
This document is a Notice of Proposed Sale of Securities pursuant to Rule 144 for Beta Bionics. Rule 144 allows for the public resale of restricted and control securities without registration if certain conditions are met. The document, therefore, formally declares an intention to sell specified securities under these regulations.
Christina Jones to sell 2,811 BBNX shares (NASDAQ: BBNX) under 10b5-1
Christina Jones has filed a Form 144 to sell 2,811 shares of Beta Bionics, Inc. (NASDAQ: BBNX) Common Stock under a 10b5-1 plan. The shares are Restricted Stock Units, with prior sales of 1,998 shares on May 21, 2026, totaling $19,880.10. This pre-scheduled sale helps insiders avoid accusations of trading on non-public information.
BBNX (NASDAQ: BBNX) affiliate files Rule 144 to sell 275 shares
An affiliate of Beta Bionics, Inc. (NASDAQ: BBNX) has filed a Rule 144 notice to sell 275 shares from an equity award, dated June 1, 2026. The filing also details previous sales by Mark Hopman of 5,329 shares on June 2, 2026, for $68,157.91, and 353 shares on March 4, 2026, for $4,084.21. As of June 4, 2026, BBNX has 44,024,631 shares outstanding.
Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information
Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) after its stock price declined over 35% following preliminary Q4 2025 financial results. The company's new patient starts were below analyst expectations, indicating a slowdown in growth. The firm is examining whether Beta Bionics' officers and directors violated securities laws or breached fiduciary duties to shareholders.
